ArticleJournal of cellular and molecular medicine2012
Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts.
Article in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Evaluation and manipulation of tissue and cellular distribution of cardiac progenitor cell-derived extracellular vesicles.Frontiers in pharmacology · 2022Article
- Systemic Mesenchymal Stem Cell-Derived Exosomes Reduce Myocardial Infarct Size: Characterization With MRI in a Porcine Model.Frontiers in cardiovascular medicine · 2020Article
- Human Cardiac Progenitor Cells Enhance Exosome Release and Promote Angiogenesis Under Physoxia.Frontiers in cell and developmental biology · 2020Article
- Cardiac Progenitor Cell-Derived Extracellular Vesicles Reduce Infarct Size and Associate with Increased Cardiovascular Cell Proliferation.Journal of cardiovascular translational research · 2019Article
- Therapeutic Application of Mesenchymal Stem Cells Derived Extracellular Vesicles for Immunomodulation.Frontiers in immunology · 2019Review
- Triggering Endogenous Cardiac Repair and Regeneration via Extracellular Vesicle-Mediated Communication.Frontiers in physiology · 2018Review
- Extracellular Vesicles Released by Human Induced-Pluripotent Stem Cell-Derived Cardiomyocytes Promote Angiogenesis.Frontiers in physiology · 2018Article
- Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells.Oncotarget · 2017Article
- Obtaining control of cell surface functionalizations via Pre-targeting and Supramolecular host guest interactions.Scientific reports · 2017Article
- Cardiac Progenitor Cells and the Interplay with Their Microenvironment.Stem cells international · 2017Review
- Potential Role of Exosomes in Mending a Broken Heart: Nanoshuttles Propelling Future Clinical Therapeutics Forward.Stem cells international · 2017Review
- Myocardial Regeneration via Progenitor Cell-Derived Exosomes.Stem cells international · 2017Review
- Extracellular vesicles and cardiovascular disease therapy.Stem cell investigation · 2017Review
- iPSC-derived human cardiac progenitor cells improve ventricular remodelling via angiogenesis and interstitial networking of infarcted myocardium.Journal of cellular and molecular medicine · 2016Article
- Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough?PloS one · 2016Article
- The Evolution of the Stem Cell Theory for Heart Failure.EBioMedicine · 2015Review
- Cellular and molecular characterization of human cardiac stem cells reveals key features essential for their function and safety.Stem cells and development · 2015Article
- Myocardial infarction models in NOD/Scid mice for cell therapy research: permanent ischemia vs ischemia-reperfusion.SpringerPlus · 2015Article
- Extracellular vesicles: potential roles in regenerative medicine.Frontiers in immunology · 2014Review
- MicroRNA-1 enhances the angiogenic differentiation of human cardiomyocyte progenitor cells.Journal of molecular medicine (Berlin, Germany) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously showed that human cardiomyocyte progenitor cells (hCMPCs) injected after myocardial infarction (MI) had differentiated into cardiomyocytes in vivo 3 months after MI. Here, we investigated the short-term (2 weeks) effects of hCMPCs on the infarcted mouse myocardium. MI was induced in immunocompromised (NOD/scid) mice, immediately followed by intramyocardial injection of hCMPCs labelled with enhanced green fluorescent protein (hCMPC group) or vehicle only (control group). Sham-operated mice served as reference. Cardiac performance was measured 2 and 14 days after MI by magnetic resonance imaging at 9.4 T. Left ventricular (LV) pressure-volume measurements were performed at day 15 followed by extensive immunohistological analysis. Animals injected with hCMPCs demonstrated a higher LV ejection fraction, lower LV end-systolic volume and smaller relaxation time constant than control animals 14 days after MI. hCMPCs engrafted in the infarcted myocardium, did not differentiate into cardiomyocytes, but increased vascular density and proliferation rate in the infarcted and border zone area of the hCMPC group. Injected hCMPCs engraft into murine infarcted myocardium where they improve LV systolic function and attenuate the ventricular remodelling process 2 weeks after MI. Since no cardiac differentiation of hCMPCs was evident after 2 weeks, the observed beneficial effects were most likely mediated by paracrine factors, targeting amongst others vascular homeostasis. These results demonstrate that hCMPCs can be applied to repair infarcted myocardium without the need to undergo differentiation into cardiomyocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.